Bladder perforation: a potential risk of early endovesical chemotherapy with mitomycin C

Abstract

The use of chemotherapeutic agents in the treatment of superficial bladder cancer is well known. In particular, mitomycin C (MMC) is globally accepted also in the early treatment after an endoscopic resection. Complications related to MMC are usually scarce as a systemic absorption is quite absent, while its use is effective for the bladder recurrence reduction. In our experience we report a female patient with a bladder perforation after an early instillation of a single dose of MMC. In this case, systemic toxicity occurred requiring subintensive care for a complete repair.